AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 46,875,000 shares of common stock of the Company at a price to the public of $1.60 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 19, 2021, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.
The Company also has granted to the underwriter a 30-day option to purchase up to an additional 7,031,250 shares of common stock at the public offering price, less underwriting discounts and commission.
The gross proceeds are expected to be approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.
The offering is being conducted pursuant to the registration statement on Form S-3 (File No. 333-238172), as amended, previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”) on June 18, 2020. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Electronic copies of the final prospectus relating to this offering, when available, may be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, by email at email@example.com or by telephone at 646-975-6996. Before investing in this offering, interested parties should read in their entirety the registration statement that the Company has filed with the SEC, which provides additional information about the Company and this offering.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
AIkido Pharma Inc.:
BioRegenx Announces Investor Update
CEO, William Resides announces that as of July 1st, 2022, BioRegenx has moved from due diligence to a binding letter of intent to merge with a public company. These steps also include drafting of the definitive agreement for final merger.
As part of the merger activity, BioRegenx has hired Dan Cortes, CPA as its CFO. This decision was made in part to Dan’s track record as an experienced corporate financial CFO with more than 20 years of progressive experience in financial operations and taxation with both private and public organizations ranging from startups to those with hundreds of millions in revenue.
Microvascular Health Solutions Developments
After 18-months of research and development, followed by rigorous testing, Microvascular Health Solutions has approved final production of a new camera capable of taking six times more video images gathered from under the tongue. The new patent-pending camera is called CapiVision™. The components for 1,000 CapiVision cameras have been ordered and production has begun with delivery expected late Q3, early Q4.
Along with development of the new CapiVision camera, the MVHS team has completed development of the 5.2.7 version of the GlycoCheck software and new video acquisition software that quality-check videos recorded by the CapiVision camera. Test results will be calculated on a new high-powered custom laptop computer capable of quickly processing results.
The next stage of software development is for the processing of the GlycoCheck video images to be transmitted to the cloud for calculation and storage of the MicroVascular Health Score™ as a Software as a Service (SaaS). This will run on the Microsoft™ Azure Platform. The development is ongoing with our technology team in the Netherlands and the first version is expected to be released Q4, 2022.
Our plan is to bring the GlycoCheck system now being used in over 140 academic research hospitals studying a wide range of conditions and diseases, into a much-anticipated targeted system for medical and professional office use that generates a personalized MicroVascular Health Report for individual patients. To support medical and professional office use, we have created a series of 19 GlycoCheck System training modules, with more coming in the future. Once a provider views the videos and takes a test for each module, and a passing score is completed for all modules, a certificate of completion is issued. The training platform is hosted by the Boston BioLife Academy, a leading training, CME credit, and in-person events company for MD’s and Practitioners across the U.S.
There are now 90 peer-reviewed published studies using GlycoCheck in major medical journals that have researched how diseases and conditions are linked to a decline in endothelial glycocalyx function and a leaky, compromised microvascular system. Those studies range from health issues like sepsis, COVID-19, kidney disease, heart disease, cerebrovascular events, psoriasis, and many more. View the entire list at https://glycocheck.com/research-and-studies/#published. If you have a specific disease or condition you wish to read more about, type the name in the “Search” function to narrow the studies down to your specific interest.
BioRegenx’ wholly owned subsidiary, NuLife Sciences announces the release of its latest product and service, TruEpigenetics via the Apple Store and Google Play. TruEpigenetics has launched on www.NuLifeSciences.com/TruEpigenetics. Now, you can discover your biological age and take control of your genetic health with a simple saliva test. The TruEpigenetics Practitioner and Patient on-boarding portal is expected for release in late Q3.
Referral Link Development for Sales Tracking
Currently, we are in the in final phase of testing of NuLife Sciences’ Hybrid-Direct Sales and Practitioner referral link program. This will allow all BioRegenx’ subsidiaries to utilize referral links, commission tracking, and account on-boarding for both our professional clients’ practices as well as their patients.
Endocalyx Pro™ Double-Blind Placebo Studies
Double-blind placebo studies on the effectiveness of Endocalyx Pro have been running since 2015. In-depth studies take years to complete, and we are just now seeing the results from those studies. These studies are in cell cultures, animal trials, as well as human studies. These studies are on the following health conditions and diseases:
Additional studies currently being written and in the approval process will be devoted to these conditions:
Emergency Room Admissions
Arterial Plaque Development
Review these studies and more at https://microvascular.com/endocalyx-pro-studies
BioRegenx, Inc., (https://bioregenx.com/) a holding company, consists of Microvascular Health Solutions, LLC, My Body Rx, LLC, and NuLife Sciences, Inc. BioRegenx and its subsidiaries combine the patented intellectual property of the breakthrough GlycoCheck medical testing device, the patented nutraceutical Endocalyx Pro, additional synergistic dietary supplement products sold under the My Body Rx brand, and a customer base of medical professionals and brand partners throughout North America.
Microvascular Health Solutions (MVHS) is a research and product development, sales, education, and marketing company that has developed the patented and clinically tested Endocalyx Pro™ dietary supplement to improve the health of the endothelial glycocalyx. In addition, MVHS manufactures, exclusively sells, and distributes the patented GlycoCheck™ software and Class 1 medical device that measures and analyzes the endothelial glycocalyx, a transparent lining inside all blood vessels.
My Body Rx™ is a manufacturing, sales and product development company that produces dietary supplements that complement and work synergistically with the patented and clinically tested Endocalyx Pro™ product to support and improve healthy aging and increase longevity.
NuLife Sciences, Inc. is a marketing and distribution company whose mission is to harness advanced technologies to redefine health and longevity. This is achieved by increasing understanding of the biology that controls lifespan and anti-aging in the human body. NuLife exclusively markets the My Body Rx™ supplement line. NuLife will also distribute GlycoCheck™, TruEpigenetics, and additional new products currently under consideration.
This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements regarding potential sales, the success of the company’s business, as well as statements that include the word believe or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of BioRegenx, Inc. to differ materially from those implied or expressed by such forward-looking statements. This press release speaks as of the date first set forth above, and BioRegenx, Inc. assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, timely development of products, inability to deliver products when ordered, inability of potential customers to pay for ordered products, and political and economic risks inherent in international trade
An Unbeatable Host of Services for WMS Can Be Yours Today with WynCore
The convenience and confidence in a company that provides total services for a WMS upgrade or modification is close at hand. Unexpected demands on the supply chain have caused you to consider an upgrade or series of modifications now. The experienced consultants at WynCore provide customized warehouse management system changes from minor adjustments to a complete overhaul for Manhattan Software.
WynCore professionals provide the plan, implantation and support for your custom needs. A seamless integration, modification and upgrade or total overhaul that fits your bottom line and demanding timeline. Call now to speak with our software developers about your warehouse management software upgrade services and customization needs by calling us at 866-996-2673.
WynCore offers you a full host of services including: design and implementation, QA Testing, customized maintenance and support, along with training. Our flexible lineup of services allows us to quickly find the best solution for you. In addition, we are proud to note that WynCore developers and project management teams are experts in both Agile and Waterfall methodologies and well versed in DEV-OPS.
As the trusted and preferred choice for Manhattan software WMS modifications needed for never-ending challenges, our team can quickly design a customized set of services to assist you in operating your warehouse flawlessly. From minor tweaks and adjustments to your WMS or a complete overhaul, WynCore consultants craft a customized plan to suit your timeline and budget.
Our support to you does not stop at the end of your WMS customization services. WynCore project management and global support teams provide assistance whenever you need it to help minimize disruptions with any arising issue, even after a modification or upgrade is completed. Why wait for your WMS improvement? Call WynCore today at 866-996-2673.
WynCore Offers Complete WMS Modifications to Enhance your Manhattan Software
WynCore can meet your pressing need for the convenience of total services for a WMS upgrade or modification. Our experienced consultants offer customized warehouse management system changes from minor adjustments to a complete overhaul for Manhattan Software. Call 866-996-2673 to speak with our software developers about your warehouse management software upgrade services and customization needs.
We offer you a full host of services including: design and implementation, QA Testing, customized maintenance and support, along with training. Your warehouse management software could use small adjustments or need a major redesign where training and support are required. Our flexible lineup of services allows us to quickly find the best solution for you. In addition, we are proud to note that WynCore developers and project management teams are experts in both Agile and Waterfall methodologies and well versed in DEV-OPS.
We are the trusted and preferred choice for Manhattan software WMS modifications needed for the challenges of today and in the future. Our developers can quickly design a customized set of services to assist you in operating your warehouse flawlessly. From minor tweaks and adjustments to your WMS or a complete overhaul, WynCore professionals craft a customized plan to suit your timeline and budget.
Our support to you does not stop at the end of your WMS customization services. WynCore project management and global support teams provide assistance whenever you need it 24/7 to help minimize disruptions with any arising issue, even after a modification or upgrade is completed.
WynCore provides the plan, implementation and support especially for you. A seamless integration, modification and upgrade or total overhaul that fits your bottom line can be in your future. Reach out today and speak with our software developers about your warehouse management software upgrade services and customization needs by calling us at 866-996-2673.